Eli Lilly just announced phase 3 clinical trial results for its new medication, retatrutide, and it could become the most ...

Eli Lilly ( LLY 2.00%) recently announced stellar results from a phase 3 clinical trial, Triumph-4, which evaluated efficacy ...

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news ...

Eli Lilly is leading the market for GLP-1 medications (for weight loss and diabetes). In a decade, Eli Lilly could be in the ...

The plaintiffs had asked the panel to create a separate multi-district litigation for the cases, arguing that the optic ...

Eli Lilly LLY and Merck MRK are both major global pharmaceutical companies with blockbuster drug portfolios and deep ...

I am bullish on healthcare stocks, especially pharmaceuticals, due to conservative valuations. Check out the healthcare ...

In November, the Trump administration resurrected a Most Favored Nation (MFN) reference pricing policy, which would tie drug ...

There is no exact known number of GLP-1 patients who say their say their sense of taste has changed since starting the ...